Xbrane Biopharma AB Strategic Asset Allocation Index
Xbrane Biopharma AB strategic asset allocation index. Xbrane Biopharma AB (XBRANE) has a Strategic Asset Allocation Index of 0.0% as of December 2025. Strategic assets (PP&E of Skr36.00K plus long-term investments of Skr-) total Skr36.00K, measured against net assets of Skr560.65 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See XBRANE equity financing ratio to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Xbrane Biopharma AB (2016–2025)
Strategic asset allocation index of Xbrane Biopharma AB from 2016 to 2025. This chart shows how Xbrane Biopharma AB's Strategic Asset Allocation Index has evolved across 10 annual periods from 2016 to 2025. As of December 2025, the index stands at 0.0%, representing strategic assets of Skr36.00K against net assets of Skr560.65 Million SEK. Check XBRANE goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Xbrane Biopharma AB Strategic Asset Allocation Index by Year (2016–2025)
Xbrane Biopharma AB strategic asset allocation index by year from 2016 to 2025. The table below presents the year-by-year Strategic Asset Allocation Index for Xbrane Biopharma AB from 2016 to 2025, covering 10 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see XBRANE company net worth.
| Year | SAAI | Strategic Assets (SEK) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 0.0% | Skr36.00K | Skr36.00K | Skr- | Skr560.65 Million | ▼ -31.1 pp |
| 2024 | 31.1% | Skr64.90 Million | Skr64.90 Million | Skr- | Skr208.54 Million | ▼ -20.4 pp |
| 2023 | 51.5% | Skr88.20 Million | Skr88.20 Million | Skr- | Skr171.34 Million | ▲ +34.8 pp |
| 2022 | 16.7% | Skr71.05 Million | Skr71.05 Million | Skr- | Skr424.89 Million | ▼ -0.4 pp |
| 2021 | 17.1% | Skr73.80 Million | Skr73.80 Million | Skr- | Skr431.74 Million | ▲ +11.6 pp |
| 2020 | 5.5% | Skr14.13 Million | Skr14.13 Million | Skr- | Skr257.71 Million | ▼ -3.3 pp |
| 2019 | 8.8% | Skr16.21 Million | Skr16.21 Million | Skr- | Skr184.32 Million | ▼ -11.4 pp |
| 2018 | 20.2% | Skr16.74 Million | Skr16.74 Million | Skr- | Skr83.07 Million | ▼ -0.8 pp |
| 2017 | 21.0% | Skr18.57 Million | Skr18.57 Million | Skr- | Skr88.41 Million | ▲ +4.3 pp |
| 2016 | 16.7% | Skr17.88 Million | Skr17.88 Million | Skr- | Skr107.30 Million | — |